Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

380 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
IMPRESS-Norway: improving public cancer care by implementing precision medicine in Norway; inclusion rates and preliminary results.
Puco K, Fagereng GL, Brabrand S, Niehusmann P, Støre Blix E, Samdal Steinskog ES, Haug Å, Fredvik Torkildsen C, Oppedal IA, Meltzer S, Flobak Å, Johansson KAM, Bjørge L, Hjortland GO, Dalhaug A, Lund JÅ, Gilje B, Grønlie Cameron M, Hovland R, Falk RS, Smeland S, Giercksky Russnes HE, Taskén K, Helland Å; InPreD Consortium; IMPRESS-Norway Consortium. Puco K, et al. Acta Oncol. 2024 May 23;63:379-384. doi: 10.2340/1651-226X.2024.28322. Acta Oncol. 2024. PMID: 38779911 Free article.
Hever kvaliteten på behandling av kreft.
Helland Å, Steinskog ESS, Blix ES, Flobak Å, Brabrand S, Puco K, Niehusmann P, Meltzer S, Oppedal IA, Haug Å, Torkildsen CF, Randen U, Gilje B, Lønning PE, Gjertsen BT, Hovland R, Russnes HG, Fagereng GL, Smeland S, Tasken K. Helland Å, et al. Among authors: lonning pe. Tidsskr Nor Laegeforen. 2024 Jan 18;144(1). doi: 10.4045/tidsskr.23.0740. Print 2024 Jan 23. Tidsskr Nor Laegeforen. 2024. PMID: 38258713 Free article. Norwegian. No abstract available.
Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer.
Yndestad S, Engebrethsen C, Herencia-Ropero A, Nikolaienko O, Vintermyr OK, Lillestøl RK, Minsaas L, Leirvaag B, Iversen GT, Gilje B, Blix ES, Espelid H, Lundgren S, Geisler J, Aase HS, Aas T, Gudlaugsson EG, Llop-Guevara A, Serra V, Janssen EAM, Lønning PE, Knappskog S, Eikesdal HP. Yndestad S, et al. Among authors: lonning pe. JCO Precis Oncol. 2023 Sep;7:e2300338. doi: 10.1200/PO.23.00338. JCO Precis Oncol. 2023. PMID: 38039432 Free PMC article.
Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Electronic address: bc.overview@ctsu.ox.ac.uk; Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Electronic address: bc.overview@ctsu.ox.ac.uk, et al. Lancet. 2023 Apr 15;401(10384):1277-1292. doi: 10.1016/S0140-6736(23)00285-4. Lancet. 2023. PMID: 37061269 Free PMC article.
Demystifying BRAF Mutation Status in Colorectal Liver Metastases : A Multi-institutional, Collaborative Approach to 6 Open Clinical Questions.
Margonis GA, Boerner T, Bachet JB, Buettner S, Moretto R, Andreatos N, Sartore-Bianchi A, Wang J, Kamphues C, Gagniere J, Lonardi S, Løes IM, Wagner D, Spallanzani A, Sasaki K, Burkhart R, Pietrantonio F, Pikoulis E, Pawlik TM, Truant S, Orlandi A, Pikouli A, Pella N, Beyer K, Poultsides G, Seeliger H, Aucejo FN, Kornprat P, Kaczirek K, Lønning PE, Kreis ME, Wolfgang CL, Weiss MJ, Cremolini C, Benoist S, D'Angelica M. Margonis GA, et al. Among authors: lonning pe. Ann Surg. 2023 Sep 1;278(3):e540-e548. doi: 10.1097/SLA.0000000000005771. Epub 2022 Dec 1. Ann Surg. 2023. PMID: 36453261
APOBEC3A/B deletion polymorphism and endometrial cancer risk.
Sofiyeva N, Krakstad C, Halle MK, O'Mara TA, Romundstad P, Hveem K, Vatten L, Lønning PE, Gansmo LB, Knappskog S. Sofiyeva N, et al. Among authors: lonning pe. Cancer Med. 2023 Mar;12(6):6659-6667. doi: 10.1002/cam4.5448. Epub 2022 Nov 16. Cancer Med. 2023. PMID: 36394079 Free PMC article.
Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers.
Batalini F, Gulhan DC, Mao V, Tran A, Polak M, Xiong N, Tayob N, Tung NM, Winer EP, Mayer EL, Knappskog S, Lønning PE, Matulonis UA, Konstantinopoulos PA, Solit DB, Won H, Eikesdal HP, Park PJ, Wulf GM. Batalini F, et al. Among authors: lonning pe. Clin Cancer Res. 2022 Nov 1;28(21):4714-4723. doi: 10.1158/1078-0432.CCR-22-0749. Clin Cancer Res. 2022. PMID: 36048535 Free PMC article.
380 results